MTHFR C677T 基因多态性与高血压患者血脂水平相关性研究

MTHFR C677T gene polymorphism and blood lipid level in hypertensive patients

目的:探究亚甲基四氢叶酸还原酶(MTHFR)C677T基因多态性与高血压患者同型半胱氨酸(Hcy)及血脂水平的关系。方法:选取2020年1~6月皖南医学院第二附属医院收治的高血压患者275例。根据MTHFR C677T基因检测结果分为CC基因型组80例、CT基因型组139例和TT基因型组56例,比较3组一般临床资料、Hcy、血脂水平(LDL-C、HDL-C、TG、TC)的差异。结果:MTHFR C677T基因多态性分布符合H-W遗传平衡定律(χ^(2)=0.096,P=0.757),样本具有区域群体代表性。CC组和CT组血清Hcy、LDL-C水平均低于TT组(P<0.05)。MTHFR C677T基因多态性与血清LDL-C水平呈正相关(r=0.134,P=0.026),血清Hcy与LDL-C水平关联性无统计学意义(r=0.070,P=0.248)。结论:高血压病患者的MTHFR C677T基因多态性与血清Hcy和LDL-C水平呈正相关,且MTHFR C677T基因多态性对患者血清LDL-C水平的影响独立于Hcy水平。MTHFR C677T基因多态性检测对于心脑血管疾病的一、二级预防有潜在作用。

Objective:To investigate the relationship between methylenetetrahydrofolate reductase(MTHFR)gene C677T polymorphism and homocysteine(Hcy)and blood lipid levels in patients with hypertension.Methods:275 patients with hypertension treated in the Second Affiliated Hospital of Wannan Medical College were recruited from January 2020 to June 2020,and divided into CC genotype group(n=80),CT genotype group(n=139)and TT genotype group(n=56)according to the results of MTHFR C677T gene test.The three groups were compared regarding the differences of general clinical data,Hcy and blood lipid levels(LDL-C,HDL-C,TG,TC).Results:The polymorphism distribution of MTHFR C677T complied with the Hardy-Weinberg equilibrium principle(χ^(2)=0.096,P=0.757),and the sample was representative for regional population.Serum Hcy and LDL-C levels were lower in CC group and CT group than in TT group(P<0.05).MTHFR C677T gene polymorphism was positively correlated with serum LDL-C levels(r=0.134,P=0.026),and there was no statistically significant difference in the correlation between serum Hcy and LDL-C levels(r=0.070,P=0.248).Conclusion:The MTHFR C677T gene polymorphism in patients with hypertension is associated with increased serum Hcy and LDL-C levels.The influence of MTHFR C677T gene polymorphism on LDL-C level of patients is independent of Hcy level.The detection of MTHFR C677T gene polymorphism may have potential effects on primary and secondary prevention of cardiovascular and cerebrovascular diseases.